What long-term studies support Cosentyx (secukinumab) efficacy?
Cosentyx’s long-term efficacy is supported by extension and long-duration follow-up data from major clinical programs across key indications, including plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). These studies track whether patients maintain symptom control over multiple years, typically using standard disease measures specific to each condition (for example, PASI for psoriasis, and ACR responses or AS disease activity measures for arthritis/axial disease) [1][2][3].
How durable are responses over time in plaque psoriasis?
In plaque psoriasis, long-term evidence comes from open-label and extension follow-ups that evaluate how many patients keep achieving and maintaining clinically meaningful responses after initial induction. The key question these programs address is whether secukinumab’s effect persists rather than only being present early after starting therapy [1][2].
Does long-term data show sustained benefit in psoriatic arthritis?
For psoriatic arthritis, long-term efficacy evidence is based on follow-up from randomized trials plus their longer extension periods, using PsA outcome measures to determine whether improvements in joints, skin, and function hold over time [2][3].
What about axial spondyloarthritis and ankylosing spondylitis?
In ankylosing spondylitis and related axial spondyloarthritis, long-term efficacy support similarly comes from extension data that continue to measure disease activity outcomes across extended treatment durations [3].
What evidence do regulatory assessments rely on?
Regulatory decisions for long-term efficacy generally rely on clinical trial results from both the core randomized periods and longer follow-up/extension studies showing maintained responses and acceptable ongoing benefit-risk over time [1][2][3]. Package insert information also summarizes the durability of effects observed in clinical programs.
What does “long-term efficacy” mean in practice?
Across studies, long-term efficacy typically means maintained (or sustained) improvement in disease activity indices and the proportion of patients who continue to respond through extended follow-up, rather than short-term symptom relief. The specific instruments vary by condition but are designed to capture sustained control over years [1][2][3].
---
Sources
- https://www.cosentyx.com/hcp/about-cosentyx/clinical-studies
- https://www.drugs.com/clinical-trials/cosentyx.html
- https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx